다발성경화증 치료를 위한 인터페론 베타의 산업적 생산

초록

Multiple sclerosis is a chronic disorder commonly occurred in the central nervous system and is an autoimmune disease. Corticosteroids are used as a short-term treatment for multiple sclerosis, but they cause side effects. Therefore, interferon beta having antiviral and anti-inflammatory effects, is used for long-term treatment. Interferon beta-1a, produced in Chinese hamster ovary cells, is glycosylated upon biosynthesis and forms glycoform, which is similar to naturally occurring protein. However, its process has disadvantages such as slow cell growth, low yield and high contamination possibility. Also, recombinant Escherichia coli is widely used for the production of interferon beta-1b due to its rapid growth and easy process scale up, but it lacks post-translational modification, leading to low activity. In addition, the produced Interferon beta-1b might cause protein aggregation due to misfolding. Alternatively, yeast can be used as a production host possessing N-glycosylation activity. Therefore, the choice of expression system in the production of interferon beta should be carefully selected in relation to the quality and yield.

키워드